Dr. Olukotun is a Mayo-Clinic-trained Cardiologist with extensive background in biopharmaceutical development, particularly in the cardiometabolic field. He has over 35 years of experience in the pharmaceutical industry and has been instrumental in the approval and success of numerous cardiology and metabolic medicines, including the first daily beta blocker and the first approved ACE inhibitor, among others.

Since 2001 Dr. Olukotun has served as CEO of CR Strategies LLC, which consults on clinical trial design and FDA strategy for pharmaceutical development. From 2014-2017 he was CEO of Epigen Pharmaceuticals, Inc., a discovery phase biotechnology company. Dr. Olukotun spent the first 20 years of his career in roles of increasing responsibility in clinical development, including multiple product approvals at Pfizer, Bristol-Myers Squibb, and Mallinckrodt.

Dr. Olukotun is currently on the Board for Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a clinical-stage biopharmaceuticals company. He was Vice Board Chair of CardioVax, Inc., a clinical-stage biopharmaceutical company (2012-2016).

Dr. Olukotun received his MD degree from the Albert Einstein College of Medicine in New York, and an MPH from Harvard University School of Public Health.